Go Pro
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
argenex SE stock logo
ARGX
argenex
$1,023.21
$910.13
$661.85
▼
$1,061.57
$64.01B0.46309,191 shs175,513 shs
Insmed, Inc. stock logo
INSM
Insmed
$118.54
$113.64
$90.39
▼
$212.75
$25.89B0.812.92 million shs1.98 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$137.99
$77.11
$22.28
▼
$176.66
$55.09B0.9130.35 million shs25.76 million shs
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$794.19
$717.52
$541.00
▼
$847.00
$81.77B0.22707,493 shs487,735 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
argenex SE stock logo
ARGX
argenex
0.00%-1.59%+19.84%+22.38%+43.67%
Insmed, Inc. stock logo
INSM
Insmed
0.00%-5.75%+20.22%+11.80%-12.90%
Moderna, Inc. stock logo
MRNA
Moderna
0.00%-4.88%+151.71%+199.59%+472.81%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
0.00%-4.78%+4.14%+32.22%+36.76%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
argenex SE stock logo
ARGX
argenex
$1,023.21
$910.13
$661.85
▼
$1,061.57
$64.01B0.46309,191 shs175,513 shs
Insmed, Inc. stock logo
INSM
Insmed
$118.54
$113.64
$90.39
▼
$212.75
$25.89B0.812.92 million shs1.98 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$137.99
$77.11
$22.28
▼
$176.66
$55.09B0.9130.35 million shs25.76 million shs
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$794.19
$717.52
$541.00
▼
$847.00
$81.77B0.22707,493 shs487,735 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
argenex SE stock logo
ARGX
argenex
0.00%-1.59%+19.84%+22.38%+43.67%
Insmed, Inc. stock logo
INSM
Insmed
0.00%-5.75%+20.22%+11.80%-12.90%
Moderna, Inc. stock logo
MRNA
Moderna
0.00%-4.88%+151.71%+199.59%+472.81%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
0.00%-4.78%+4.14%+32.22%+36.76%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
argenex SE stock logo
ARGX
argenex
2.88
Moderate Buy$1,157.5013.12% Upside
Insmed, Inc. stock logo
INSM
Insmed
3.00
Buy$205.5273.38% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.17
Hold$80.53-41.64% Downside
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
2.60
Moderate Buy$800.360.78% Upside

Current Analyst Ratings Breakdown

Latest INSM, REGN, ARGX, and MRNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/28/2026
Moderna, Inc. stock logo
MRNA
Moderna
CLSA logo
CLSA
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeOutperform
8/28/2026
Moderna, Inc. stock logo
MRNA
Moderna
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageHold
8/28/2026
Moderna, Inc. stock logo
MRNA
Moderna
William Blair logo
William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform
8/28/2026
Moderna, Inc. stock logo
MRNA
Moderna
Bradesco Corretora logo
Bradesco Corretora
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeOutperform
8/28/2026
Moderna, Inc. stock logo
MRNA
Moderna
Argus logo
Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Buy$180.00
8/26/2026
argenex SE stock logo
ARGX
argenex
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$1,350.00 ➝ $1,415.00
8/26/2026
argenex SE stock logo
ARGX
argenex
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeNeutral ➝ Buy$960.00 ➝ $1,400.00
8/25/2026
Moderna, Inc. stock logo
MRNA
Moderna
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeUnderperform ➝ Peer Perform
8/24/2026
Moderna, Inc. stock logo
MRNA
Moderna
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetEqual Weight$48.00 ➝ $125.00
8/24/2026
argenex SE stock logo
ARGX
argenex
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Hold
8/21/2026
Moderna, Inc. stock logo
MRNA
Moderna
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetUnderweight$40.00 ➝ $77.00
(Data available from 8/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
argenex SE stock logo
ARGX
argenex
$4.25B15.07$21.33 per share47.97$118.34 per share8.65
Insmed, Inc. stock logo
INSM
Insmed
$1.14B22.76N/AN/A$3.46 per share34.26
Moderna, Inc. stock logo
MRNA
Moderna
$1.94B28.34N/AN/A$22.14 per share6.23
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$15.53B5.26$41.98 per share18.92$295.66 per share2.69
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
argenex SE stock logo
ARGX
argenex
$1.29B$26.0439.2927.641.0632.19%43.59%36.66%N/A
Insmed, Inc. stock logo
INSM
Insmed
-$1.28B-$4.11N/A45.42N/A-76.94%-123.94%-44.30%10/29/2026 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$7.99N/AN/AN/A-141.43%-28.30%-19.39%11/5/2026 (Estimated)
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$4.50B$40.4619.6315.721.3527.86%13.47%10.34%10/28/2026 (Estimated)

Latest INSM, REGN, ARGX, and MRNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Insmed, Inc. stock logo
INSM
Insmed
-$0.6724-$0.06+$0.6124-$0.06$395.50 million$425.49 million
7/31/2026Q2 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$2.03-$1.97+$0.06-$1.97$102.93 million$145.00 million
7/30/2026Q2 2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$10.16$14.29+$4.13$12.23$3.82 billion$4.29 billion
7/21/2026Q2 2026
argenex SE stock logo
ARGX
argenex
$5.86$7.32+$1.46$7.32$1.45 billion$1.54 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
argenex SE stock logo
ARGX
argenex
N/AN/AN/AN/AN/A
Insmed, Inc. stock logo
INSM
Insmed
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$3.760.47%N/A9.29%N/A

Latest INSM, REGN, ARGX, and MRNA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/30/2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
quarterly$0.940.46%8/18/20268/18/20268/31/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
argenex SE stock logo
ARGX
argenex
N/A
5.12
4.89
Insmed, Inc. stock logo
INSM
Insmed
0.74
3.72
3.40
Moderna, Inc. stock logo
MRNA
Moderna
0.09
2.29
2.18
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
0.06
3.34
2.78

Institutional Ownership

CompanyInstitutional Ownership
argenex SE stock logo
ARGX
argenex
60.32%
Insmed, Inc. stock logo
INSM
Insmed
N/A
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
83.31%

Insider Ownership

CompanyInsider Ownership
argenex SE stock logo
ARGX
argenex
2.43%
Insmed, Inc. stock logo
INSM
Insmed
2.10%
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
6.97%
CompanyEmployeesShares OutstandingFree FloatOptionable
argenex SE stock logo
ARGX
argenex
1,86362.56 million61.04 millionOptionable
Insmed, Inc. stock logo
INSM
Insmed
1,664218.38 million213.80 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
4,700399.24 million356.12 millionOptionable
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
15,410102.96 million95.78 millionOptionable

Recent News About These Companies

Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
August 30 at 12:00 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/30/3352978/9788/en/bronstein-gewirtz-grossman-llc-urges-regeneron-pharmaceuticals-inc-investors-to-act-class-action-filed-alleging-investor-harm.html
Van ECK Associates Corp Has $40.74 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN
August 30 at 5:44 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-van-eck-associates-corp-has-4074-million-holdings-in-regeneron-pharmaceuticals-inc-regn-2026-08-30/
Nissay Asset Management Corp Japan Increases Stock Position in Regeneron Pharmaceuticals, Inc. $REGN
August 30 at 5:43 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-nissay-asset-management-corp-japan-increases-stock-position-in-regeneron-pharmaceuticals-inc-regn-2026-08-30/
Wellington Management Group LLP Trims Stock Position in Regeneron Pharmaceuticals, Inc. $REGN
August 30 at 5:36 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-wellington-management-group-llp-trims-stock-position-in-regeneron-pharmaceuticals-inc-regn-2026-08-30/
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Greenwood Capital Associates LLC
August 30 at 4:23 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-regeneron-pharmaceuticals-inc-regn-shares-purchased-by-greenwood-capital-associates-llc-2026-08-30/
Regeneron Pharmaceuticals (REGN) As Pasatru Approval Tests An Undervalued View
August 29 at 10:43 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/regeneron-pharmaceuticals-regn-pasatru-approval-021530961.html
Faruqi & Faruqi, LLP Urges Regeneron Pharmaceuticals, Inc. (REGN) Investors to Seek Counsel Before the September 14, 2026 Lead Plaintiff Deadline in the Securities Class Action
August 29 at 9:41 PM  |  newsfilecorp.comN
Regeneron Pharmaceuticals (REGN) Wins FDA Approval For Pasatru In Adult FOP
August 29 at 5:42 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/regeneron-pharmaceuticals-regn-wins-fda-201430933.html
Lombard Odier Asset Management Europe Ltd Sells 11,917 Shares of Regeneron Pharmaceuticals, Inc. $REGN
August 29 at 6:40 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-lombard-odier-asset-management-europe-ltd-sells-11917-shares-of-regeneron-pharmaceuticals-inc-regn-2026-08-29/
Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Kimelman & Baird LLC
August 29 at 6:32 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-regeneron-pharmaceuticals-inc-regn-shares-bought-by-kimelman-baird-llc-2026-08-29/
Kimelman & Baird LLC Makes New $17.25 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN
August 29 at 6:32 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-kimelman-baird-llc-makes-new-1725-million-investment-in-regeneron-pharmaceuticals-inc-regn-2026-08-29/
Rakuten Investment Management Inc. Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN
August 29 at 6:18 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-rakuten-investment-management-inc-grows-stock-holdings-in-regeneron-pharmaceuticals-inc-regn-2026-08-29/
Glenview Trust Co Takes $3.07 Million Position in Regeneron Pharmaceuticals, Inc. $REGN
August 29 at 6:08 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-glenview-trust-co-takes-307-million-position-in-regeneron-pharmaceuticals-inc-regn-2026-08-29/
Regeneron Pharmaceuticals, Inc. (REGN) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before September 14, 2026 Lead Plaintiff Deadline
August 28 at 12:06 PM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/regeneron-pharmaceuticals-inc-regn-investors-securities-fraud-class-action-filed-contact-hagens-berman-before-september-14-2026-lead-plaintiff-deadline-302862825.html
Regeneron Pharmaceuticals, Inc. $REGN Stock Holdings Decreased by Harvey Capital Management Inc.
August 28 at 6:08 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-regeneron-pharmaceuticals-inc-regn-stock-holdings-decreased-by-harvey-capital-management-inc-2026-08-28/
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Jefferies Financial Group Inc.
August 28 at 6:01 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-regeneron-pharmaceuticals-inc-regn-shares-acquired-by-jefferies-financial-group-inc-2026-08-28/
Empowered Funds LLC Purchases 18,345 Shares of Regeneron Pharmaceuticals, Inc. $REGN
August 28 at 4:40 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-empowered-funds-llc-purchases-18345-shares-of-regeneron-pharmaceuticals-inc-regn-2026-08-28/
Can Regeneron (REGN)’s Rare-Disease Win Move the Earnings Needle?
August 27, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/regeneron-regn-rare-disease-win-210410578.html
Can Regeneron (REGN)’s Rare-Disease Win Move the Earnings Needle?
August 27, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/can-regeneron-regns-rare-disease-win-move-the-earnings-needle-1821012/
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN
August 27, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-regeneron-pharmaceuticals-inc-of-class-action-lawsuit-and-upcoming-deadlines--regn-302862171.html
Regeneron Pharmaceuticals (REGN) Adjusts Course Amid Mixed Results in Melanoma Drug Trials
August 27, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/regeneron-pharmaceuticals-regn-adjusts-course-124300443.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

argenex stock logo

argenex NASDAQ:ARGX

$1,023.21 0.00 (0.00%)
As of 08/28/2026 04:00 PM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Insmed stock logo

Insmed NASDAQ:INSM

$118.54 0.00 (0.00%)
As of 08/28/2026 04:00 PM Eastern

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Moderna stock logo

Moderna NASDAQ:MRNA

$137.99 0.00 (0.00%)
As of 08/28/2026 04:00 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Regeneron Pharmaceuticals stock logo

Regeneron Pharmaceuticals NASDAQ:REGN

$794.19 0.00 (0.00%)
As of 08/28/2026 04:00 PM Eastern

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas